GLP1R and diabetes mellitus: Small molecules that activate the receptor for another incretin, GLP1, are clinical mainstays for diabetes treatment but induce nausea as an adverse side effect through area postrema excitatory neurons (Drucker and Nauck, 2006; Zhang et al., 2021).